FDA May Revisit Antidepressant “Black Box” Suicidality Warning

FDA will monitor emerging data on suicides and antidepressants as it becomes available to determine if an uptick in suicides among adolescents is associated with the decline in prescriptions for antidepressants that followed the addition of a "black box" warning to labeling for the products